...
首页> 外文期刊>Oncology: International Journal of Cancer Research and Treatment >Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
【24h】

Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.

机译:TP53的等位基因缺失与原发性人子宫内膜癌中p53蛋白的过表达无关。

获取原文
获取原文并翻译 | 示例
           

摘要

We examined loss of heterozygosity (LOH) at the TP53 gene in primary human endometrial carcinomas (EC), and investigated the relationship between allelic loss, p53 protein overexpression, pRb-1 pathway alterations and MIB-1 proliferative activity. Applying the non-isotopic PCR-RFLP/VNTR-silver staining techniques, we investigated TP53 LOH in 46 tumors at four polymorphic loci. Out of 42 informative carcinomas, LOH was found in 19% of the cases studied. In general, there was no significant relationship between LOH and the clinical and pathological variables of cancer, including patient age, clinical stage, histological grade or depth of myometrial invasion. Interestingly, none of 7 tumors associated with hyperplasia revealed allelic imbalance, whereas 8 of 27 (30%) tumors without hyperplasia exhibited LOH (p=0.312; Fisher's exact test). Overexpression of nuclear p53 was not correlated with allelic loss at TP53 (p=0.336, Fisher's exact test). It is worth pointing out that p53 immunoreactivity was significantly related to proliferative activity of cancer (R=0.42, p=0.0037; Spearman's rank correlation test). A tendency towards a poorer outcome was reported in EC patients displaying TP53 LOH during short-time follow-up (p=0.093; log-rank test). None of the tumors simultaneously showed LOH at TP53 and RB1 genes (R=-0.211, p=0.16; Spearman's rank correlation test). p16INK4A alterations (LOH and gene deletion) occurred concomitantly, with 3 tumors showing the TP53 allelic loss, whereas the cyclin D1/cdk4 complex was overexpressed in a case with TP53 LOH. Altogether, losses at TP53 were not associated with p53 nuclear overexpression, but may affect a subset of EC patients characterized by an unfavorable prognosis at short-time follow-up. Allelic loss at TP53 seems to arise independently of LOH at the RB1 gene in carcinomas of the uterine corpus in humans. Disruptions at p16INK4A and/or cdk4/cyclin D1 concomitantly occurring with TP53 LOH may participate in the development of a subset of endometrioid-type ECs.
机译:我们检查了原发性人类子宫内膜癌(EC)中TP53基因的杂合性(LOH)丧失,并研究了等位基因丧失,p53蛋白过表达,pRb-1途径改变和MIB-1增殖活性之间的关系。应用非同位素PCR-RFLP / VNTR-银染色技术,我们在四个多态性位点的46个肿瘤中研究了TP53 LOH。在42例信息性癌中,有19%的病例发现了LOH。通常,LOH与癌症的临床和病理变量之间无显着相关性,包括患者年龄,临床分期,组织学等级或肌层浸润深度。有趣的是,与增生相关的7个肿瘤中没有一个显示等位基因失衡,而没有增生的27个肿瘤中的8个(30%)没有LOH(p = 0.312; Fisher精确检验)。核p53的过表达与TP53的等位基因缺失无关(p = 0.336,Fisher精确检验)。值得指出的是,p53免疫反应性与癌症的增殖活性显着相关(R = 0.42,p = 0.0037; Spearman秩相关检验)。据报道,在短期随访中显示TP53 LOH的EC患者有较差结果的趋势(p = 0.093;对数秩检验)。没有一个肿瘤同时在TP53和RB1基因上显示LOH(R ​​= -0.211,p = 0.16; Spearman秩相关检验)。伴随发生p16INK4A改变(LOH和基因缺失),其中3个肿瘤显示TP53等位基因缺失,而在TP53 LOH的情况下,cyclin D1 / cdk4复合物过表达。总的来说,TP53的丢失与p53核过表达无关,但可能会影响一部分EC患者,这些患者在短期随访中预后不良。在人子宫体癌中,TP53的等位基因缺失似乎与LOH在RB1基因处无关。与TP53 LOH同时发生的p16INK4A和/或cdk4 / cyclin D1的破坏可能参与子宫内膜样EC子集的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号